HomeCompareSNYYF vs ABBV

SNYYF vs ABBV: Dividend Comparison 2026

SNYYF yields 2.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNYYF wins by $74.94M in total portfolio value· pulled ahead in Year 3
10 years
SNYYF
SNYYF
● Live price
2.66%
Share price
$1.39
Annual div
$0.04
5Y div CAGR
93.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$75.04M
Annual income
$68,183,425.63
Full SNYYF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SNYYF vs ABBV

📍 SNYYF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNYYFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNYYF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNYYF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNYYF
Annual income on $10K today (after 15% tax)
$225.98/yr
After 10yr DRIP, annual income (after tax)
$57,955,911.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SNYYF beats the other by $57,934,855.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNYYF + ABBV for your $10,000?

SNYYF: 50%ABBV: 50%
100% ABBV50/50100% SNYYF
Portfolio after 10yr
$37.57M
Annual income
$34,104,098.69/yr
Blended yield
90.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SNYYF
No analyst data
Altman Z
1.9
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNYYF buys
0
ABBV buys
0
No recent congressional trades found for SNYYF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNYYFABBV
Forward yield2.66%3.06%
Annual dividend / share$0.04$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR93.5%40.6%
Portfolio after 10y$75.04M$102.3K
Annual income after 10y$68,183,425.63$24,771.77
Total dividends collected$74.49M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNYYF vs ABBV ($10,000, DRIP)

YearSNYYF PortfolioSNYYF Income/yrABBV PortfolioABBV Income/yrGap
1$11,214$514.44$11,550$430.00$336.00ABBV
2$13,043$1,043.30$13,472$627.96$429.00ABBV
3← crossover$16,150$2,194.32$15,906$926.08+$244.00SNYYF
4$22,194$4,913.62$19,071$1,382.55+$3.1KSNYYF
5$35,959$12,211.36$23,302$2,095.81+$12.7KSNYYF
6$74,256$35,779.25$29,150$3,237.93+$45.1KSNYYF
7$213,066$133,612.72$37,536$5,121.41+$175.5KSNYYF
8$921,296$693,315.05$50,079$8,338.38+$871.2KSNYYF
9$6,407,199$5,421,412.90$69,753$14,065.80+$6.34MSNYYF
10$75,039,129$68,183,425.63$102,337$24,771.77+$74.94MSNYYF

SNYYF vs ABBV: Complete Analysis 2026

SNYYFStock

Sany Heavy Equipment International Holdings Company Limited, an investment holding company, engages in the manufacture and sale of mining equipment, logistics equipment, robotic, smart mine products, and spare parts. It operates in two segments, Mining Equipment and Logistics Equipment. The Mining Equipment segment provides coal mining machinery products, including road headers, such as soft rock and hard rock road headers, integrated excavation, bolting, and self-protection machinery; mining equipment consisting of coal mining machines, hydraulic support system, scraper conveyors, etc.; non-coal mining machinery products comprising tunnel road headers and mining machines; mining transport equipment, including mechanical drive off-highway and electric drive off-highway dump trucks, widebody vehicles, and other relevant products; spare parts; robotic products, such as robotic system integration, mobile robots, and electric forklifts; and smart mine products, including unmanned driving, automated integrated mining, and smart mine operation systems. The Logistic Equipment segment offers container equipment, such as front loaders, stacking machines and quayside gantry cranes, etc.; bulk material equipment, which comprise grippers, elevated hoisting arms, etc.; and general equipment, including heavy-weight forklifts, telehandlers, etc. In addition, the company provides maintenance and property development services. It operates in Mainland China, rest of Asia, the European Union, the United States, and internationally. The company was founded in 2004 and is headquartered in Shenyang, the People's Republic of China. Sany Heavy Equipment International Holdings Company Limited is a subsidiary of Sany Hongkong Group Limited.

Full SNYYF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SNYYF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNYYF vs SCHDSNYYF vs JEPISNYYF vs OSNYYF vs KOSNYYF vs MAINSNYYF vs JNJSNYYF vs MRKSNYYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.